A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML
Clinical trial NCT03591510 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03591510
- Sponsor
- Novartis Pharmaceuticals
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-13
- Primary completion
- 2029-05-18
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.